Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Grace L. Smith

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3171-2911; OpenAlex author ID A5059256779. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2021: 1 paper · 2022: 5 papers · 2023: none · 2024: 2 papers

Papers 8

  1. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  2. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  3. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  4. Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Last author DOI 10.1016/j.ctro.2022.04.007↗
  5. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.04.044↗
  6. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  7. Brain Metastasis from Pancreatic Cancer: Our Experience and Systematic Review. Co-author DOI 10.1016/j.wneu.2022.07.060↗
  8. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2020.11.006↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Albert C. Koong · 7 shared papers, 2021–2024 · strength 0.89
  2. Cullen M. Taniguchi · 7 shared papers, 2021–2024 · strength 0.89
  3. Eugene Jon Koay · 7 shared papers, 2021–2024 · strength 0.89
  4. Ethan Bernard Ludmir · 5 shared papers, 2022–2024 · strength 0.67
  5. Matthew H. G. Katz · 5 shared papers, 2022–2024 · strength 0.65
  6. Robert A. Wolff · 4 shared papers, 2022–2024 · strength 0.49
  7. Naruhiko Ikoma · 3 shared papers, 2022–2024 · strength 0.39
  8. Michael P. Kim · 3 shared papers, 2022–2024 · strength 0.39
  9. Ching-Wei David Tzeng · 3 shared papers, 2022–2024 · strength 0.39
  10. Suyu Liu · 2 shared papers, 2024 · strength 0.31
  11. Jason A. Willis · 2 shared papers, 2024 · strength 0.31
  12. Ramez Kouzy · 2 shared papers, 2021–2024 · strength 0.26
  13. Shubham Pant · 2 shared papers, 2022–2024 · strength 0.25
  14. Shalini Moningi · 2 shared papers, 2021–2022 · strength 0.24
  15. Anirban Maitra · 2 shared papers, 2022 · strength 0.24
  16. Michael James Overman · 2 shared papers, 2022 · strength 0.23
  17. Eric Peter Tamm · 2 shared papers, 2022 · strength 0.23
  18. Huamin Wang · 2 shared papers, 2022 · strength 0.22
  19. Mohamed Zaid · 2 shared papers, 2022 · strength 0.22
  20. Christopher H. Crane · 2 shared papers, 2022 · strength 0.22
  21. Manoop S. Bhutani · 2 shared papers, 2021–2022 · strength 0.22
  22. Joseph M. Herman · 2 shared papers, 2021–2022 · strength 0.22
  23. Hop S. Tran Cao · 1 shared paper, 2024 · strength 0.16
  24. Christopher Shi · 1 shared paper, 2024 · strength 0.16
  25. Alexander Dean Sherry · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.